Maneiro Melon Nicolas M, Velazquez Martin Maite, Huertas Nieto Sergio, Albarran Gonzalez-Trevilla Agustin, Sarnago Cebada Fernando, Cruz Utrilla Alejandro, Hinojosa Camargo Williams, Aguilar Colindres Ricardo, Melendo Viu Maria, Lopez Gude Maria Jesus, Morales Ruiz Rafael, Perez Nuñez Marta, Arribas Ynsaurriaga Fernando, Escribano Subias Pilar
Cardiology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (IMAS12), 28041 Madrid, Spain.
J Clin Med. 2023 Jan 23;12(3):905. doi: 10.3390/jcm12030905.
(1) Background: Pulmonary endarterectomy (PEA) is the "gold standard" treatment for operable patients with chronic thromboembolic pulmonary hypertension (CTEPH). Persistent pulmonary hypertension (PH) after PEA confers a worse prognosis. Balloon pulmonary angioplasty (BPA) could represent a useful therapy in this setting, but evidence about its effectiveness and safety in patients with previous PEA is limited. (2) Methods: A total of 14 patients with persistent PH after PEA were treated with BPA in a single PH center. Hemodynamic and clinical effects of BPA and complications of the procedure were retrospectively collected. (3) Results: After BPA, the mean pulmonary arterial pressure fell from 50.7 ± 15.3 mmHg to 38.0 ± 7.9 mmHg (25.0% decrease; 95% confidence interval (CI) 14.0-35.5%; = 0.01). Pulmonary vascular resistances were reduced from 8.5 ± 3.6 WU to 5.3 ± 2.2 WU (37.6% decrease; 95% CI 18.8-56.5%; = 0.01). WHO functional class was also improved with BPA. Severe BPA-related complications were infrequent and no periprocedural deaths were observed. (4) Conclusions: BPA is an effective and safe therapy for patients with CTEPH and persistent PH after PEA.
(1) 背景:肺动脉内膜剥脱术(PEA)是可手术治疗的慢性血栓栓塞性肺动脉高压(CTEPH)患者的“金标准”治疗方法。PEA术后持续性肺动脉高压(PH)预后较差。球囊肺动脉血管成形术(BPA)可能是这种情况下的一种有效治疗方法,但关于其在既往接受过PEA治疗的患者中的有效性和安全性的证据有限。(2) 方法:在一个单一的肺动脉高压中心,对14例PEA术后持续性PH患者进行了BPA治疗。回顾性收集了BPA的血流动力学和临床效果以及该手术的并发症。(3) 结果:BPA术后,平均肺动脉压从50.7±15.3 mmHg降至38.0±7.9 mmHg(下降25.0%;95%置信区间(CI)14.0 - 35.5%;P = 0.01)。肺血管阻力从8.5±3.6 WU降至5.3±2.2 WU(下降37.6%;95% CI 18.8 - 56.5%;P = 0.01)。BPA还改善了世界卫生组织功能分级。严重的BPA相关并发症很少见,且未观察到围手术期死亡。(4) 结论:BPA是治疗CTEPH且PEA术后持续性PH患者的一种有效且安全的治疗方法。